BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH - News), today announced the resignation of Mark S. Florence from his position as the Company’s Vice President of Sales and Marketing. At the same time, the Company announced the appointment of Lamont Baskett and Jim Thompson to Area Vice Presidents of the East and West Regions, respectively.
“I would like to thank Mark for his service and dedication to the Company and wish him well in his new venture,” stated Ali Haghighi-Mood, Chief Executive Officer of Cambridge Heart, Inc.
Together, Mr. Baskett and Mr. Thompson have 16 years experience with Cambridge Heart. Both individuals joined the Company as Regional Sales Managers and advanced to senior roles within the Sales organization. Most recently, each held the position of Area Director, managing the direct sales force and working closely with their St. Jude Medical counterparts. Mr. Baskett and Mr. Thompson will report to Cambridge Heart’s Chief Executive Officer Ali Haghighi-Mood.
“Lamont and Jim have an excellent understanding of MTWA technology and its role in the cardiology space,” stated Ali Haghighi-Mood. “With their combined leadership and experience, I am confident that Lamont and Jim will make significant contributions toward our goal of driving revenue growth”.
About Cambridge Heart, Inc.
Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company’s products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the U.S. also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Bedford, Massachusetts, and is traded on the OTCBB under the symbol CAMH.
Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of our MTWA technology, failure of our sales and marketing partner to market our products effectively, inability to hire and retain qualified clinical applications specialists in our target markets, failure to obtain or maintain adequate levels of third-party reimbursement for use of our MTWA test, customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
Contact: Cambridge Heart, Inc. Investor Relations, 781-271-1200 x450 www.cambridgeheart.com
Source: Cambridge Heart, Inc.
